Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- FY2015 Recruitment Plan: Eisai to Resume Offering Jobs to New Graduates
April 15, 2014
- Novartis Pharma Notified Police about Metal Object Found in Voltaren Product
April 15, 2014
- Hisamitsu Total Sales Up 5.5% but Domestic Ethical Drug Sales Down 1.8%
April 14, 2014
- Patient Enrollment for PI Trial of Anticancer Drug HF10 in US Completed, Takara Bio
April 14, 2014
- RaQualia, Asahi Kasei Pharma Conclude Joint Drug Discovery Research
April 14, 2014
- 10% of Valsartan Franchise Prescriptions Switched to Other ARBs, Azilva, Micamlo Top Lists
April 11, 2014
- Chugai Files NDA for Vemurafenib for Melanoma with BRAF Mutation, Roche Diagnostics Files for Companion Diagnostics
April 11, 2014
- 17 Patients Who Took Xeplion Have Died since November Launch
April 10, 2014
- Kyowa Kirin Completes Biopharmaceutical API Manufacturing Facility, Eying Start of Operations from 2016
April 10, 2014
- Announcement: 7th Annual Marketing Excellence Japan 2014 – Westin Tokyo, May 13 – 14
April 9, 2014
- US Jury Orders Takeda to Pay US$6 Billion in Punitive Damages
April 9, 2014
- GSK Voluntarily Recalls Paxil in Japan, No Reports of Adverse Reactions
April 9, 2014
- ViiV, Shionogi to Copromote Anti-HIV Drug Tivicay at 100 Major Facilities
April 9, 2014
- DSP Subsidiary Sunovion Launches Antiepileptic Drug Aptiom in US
April 9, 2014
- Livalo Lawsuit: Does Use of “PITAVA” by Generic Makers Infringe Kowa Trademark?
April 9, 2014
- Ethical Drug Sales Up 3.0% in February Due to Flu Epidemic: Crecon Report
April 9, 2014
- Bayer Yakuhin Sales Up 16.5% Driven by New Product Growth
April 9, 2014
- Oncolys, BMS End Collaboration for Anti-HIV Drug Development
April 9, 2014
- Santen Licenses Tafluprost Marketing Rights in US to Oak Pharmaceuticals
April 9, 2014
- Sun Deal Not Meant to Sever Ties with Ranbaxy: Daiichi Sankyo Pres.
April 8, 2014
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…